Table S4. Results of association analysis of 10 tagger SNPs on NFATC1 gene with post-transplant BPAR episodes using multivariable regression analysis adjusted by CsA/TAC usage and sirolimus administration.

SNPs	Model	OR	95% CIs	P value
rs139536097	Additive	0.97	0.49–1.91	0.94
	Dominant	1.03	0.47–2.25	0.95
	Recessive	0.61	0.06–6.15	0.67
	HOM	0.62	0.06–6.25	0.68
	HET	1.09	0.48–2.49	0.83
rs560385670	Additive	0.28	0.03–2.41	0.24
	Dominant	0.28	0.03–2.41	0.24
rs2230112	Additive	0.81	0.42–1.57	0.54
	Dominant	0.76	0.38–1.52	0.43
	Recessive	2.35	0.14–39.13	0.55
	HOM	2.18	0.13–36.45	0.59
	HET	0.71	0.35–1.47	0.36
rs201850664	Additive	1.54	0.09–25.96	0.77
	Dominant	1.54	0.09–25.96	0.77
rs25657	Additive	0.69	0.29–1.62	0.39
	Dominant	0.71	0.29–1.70	0.44
	HET	0.74	0.31–1.79	0.50
rs373993229	Additive	0.88	0.07–10.29	0.92
	Dominant	0.88	0.07–10.29	0.92
rs189757547	Additive	1.06	0.063–18.06	0.97
	Dominant	1.06	0.063–18.06	0.97
rs535298168	Additive	1.47E–09	–	0.99
	Dominant	1.47E–09	–	0.99
rs548161343	Additive	1.52E–09	–	0.99
	Dominant	1.52E–09	–	0.99
rs753386603	Additive	7.43E–10	–	0.99
	Dominant	7.43E–10	–	0.99

*, P value less than adjusted P value (0.05/14=0.0036) was considered as statistical significant. BPAR, biopsy-proven acute rejection; SNPs, single nucleotide polymorphisms; OR, odds ratio; CIs, confidential intervals; CsA, cyclosporine A; TAC, tacrolimus.